… 75 g/m 2 as in the pilot study but the ADM dose was 330 mg/m 2 compared to 420 mg/m 2 .
… g/m 2 of IFO, as in the most recent protocols. When the total dose of ifosfamide was 60–75 g/…

Background: Massive endoprostheses provide orthopaedic oncologists with many reconstructive
options after tumor resection, although failure rates are high. Because the number of …

Giant cell tumor is still one of the most controversial and discussed bone tumors. Surgical
treatment options include intralesional excision or segmental resection. Curettage has a higher …

Background Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects.
The long-term efficacy and safety of edoxaban as compared with warfarin in patients with …

Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …

Background Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal disease
caused by misfolded transthyretin. Despite advances in slowing disease progression, …

The metabolic syndrome, which is a set of lipid and nonlipid risk factors of metabolic origin
linked with insulin resistance, is believed to be associated with an elevated risk for …

Studies on new procedures for bone reconstruction suggest that autologous cells seeded on
a resorbable scaffold can improve the treatment of bone defects. It is important to develop …

BACKGROUND The evaluation variables influencing systemic and local recurrence and
final outcome are extremely important in defining risk‐adapted treatments for patients with …

BACKGROUND: Vitamin K antagonists have been the standard oral antithrombotic used for
more than a half century for prevention and treatment of thromboembolism. Their limitations …